News
May 2022
MR-proADM
DiaSorin and Thermo Fisher Scientific enter into a partnership on B·R·A·H·M·S MR-proADM for precise assessment of disease severity in critical care
DiaSorin and Thermo Fisher Scientific, the world leader in serving science, entered in a new and long-term agreement on Thermo Fisher’s biomarker testing mid-regional adrenomedullin (B·R·A·H·M·S MR-proADM). The agreement expands an already long-standing relationship between the companies for the biomarker testing using Thermo Fisher’s procalcitonin (B·R·A·H·M·S PCT). DiaSorin will develop and commercialize the new chemiluminescent immunoassay, LIASON® B·R·A·H·M·S MR-proADM™, for the quantification of MR-proADM in human plasma samples. The new test will be part of DiaSorin’s assay portfolio for the automated LIASON® CLIA analyzer family and will subsequently increase the availability of this biomarker for the diagnosis and critical care of patients with a first launch in Europe. MR-proADM is an endothelial marker that accurately indicates disease severity and progression due to organ dysfunction in patients suffering from, for example, infectious disease or sepsis. Recent publications (Gonzales Del Castillo et al., Eur J Intern Med 2021; 88:104-113; Saeed et al., Crit Care 2019; 23 (1):40) show that MR-proADM also identifies medically stable patients, which allows to de-escalate therapy or patient transfer to a lower level of care. The clinical utility of MR-proADM leads to an economic benefit by an improved allocation of hospital resources.
For more information please see here >
February 2022
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2021 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2021...
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2021 Results >
News Archive
2021
October 2021
Financial Reports
Thermo Fisher Scientific Reports Third Quarter 2021 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 3, 2021...
Thermo Fisher Scientific Reports Third Quarter 2021 Results >
October 2021
Corporate Social Responsibility
Thermo Fisher Scientific Publishes 2020 Corporate Social Responsibility Report
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published its 2020 Corporate Social Responsibility (CSR) report, reflecting its commitment to society, stakeholders and environmental, social and governance (ESG) efforts...
Thermo Fisher Scientific Publishes 2020 Corporate Social Responsibility Report >
A Letter From Our CEO On Corporate Social Responsibility >
July 2021
Financial Reports
Thermo Fisher Scientific Reports Second Quarter 2021 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 3, 2021...
Thermo Fisher Scientific Reports Second Quarter 2021 Results >
June 2021
MR-proADM / COVID-19
Midregional proadrenomedullin safely reduces hospitalization in a low severity cohort with infections in the ED: a randomized controlled multi-centre interventional pilot study
The midregional fragment of proadrenomedullin (MR-proADM) is known to provide accurate short-, mid- and long term prognostic information in the triage and multi-dimensional risk assessment of patients in the emergency department (ED). In two independent observational cohorts MR-proADM values identified low disease severity patients without risk of disease progression in the ED with no 28 days mortality that wouldn´t require hospitalization...
Gonzalez Del Castillo, J et al., Eur J Intern Med. 2021 Jun;88:104-113 >
May 2021
MR-proADM / COVID-19
MR-proADM as marker of endotheliitis predicts COVID-19 severity
Early identification of patients at high risk of progression to severe COVID-19 constituted an unsolved challenge. Although growing evidence demonstrates a direct association between endotheliitis and severe COVID-19, the role of endothelial damage biomarkers has been scarcely studied...
Guadiana-Romualdo, L et al., Eur J Clin Invest. 2021 May;51(5):e13511 >
April 2021
Financial Reports
Thermo Fisher Scientific Reports First Quarter 2021 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021....
Thermo Fisher Scientific Reports First Quarter 2021 Results >
March 2021
MR-proADM / COVID-19
Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department
The review provides evidence related to MR-proADM as a triaging tool in avoiding unnecessary admissions to hospital and/ or inadequate discharge, and identifying patients most at risk of deterioration. It also covers the use of MR-proADM in the context of COVID-19...
Saeed, K et al., Expert Rev Mol Diagn. 2021 Apr;21(4):397-404 >
February 2021
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2020...
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results >
January 2021
MR-proADM / COVID-19
The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study
Increased levels of MR-proADM on admission and during hospital stay were independently associated with in-hospital mortality and may allow a better risk stratification, and particularly rule-out of fatal outcome, in COVID-19 patients...
Gregoriano,C et al., CCLM 2020-1295 >
2020
October 2020
Financial Reports
Thermo Fisher Scientific Reports Third Quarter 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020...
Thermo Fisher Scientific Reports Third Quarter 2020 Results >
August 2020
MR-proADM / COVID-19
Effectiveness of Mid-Regional Pro-Adrenomedullin (MR-proADM) as Prognostic Marker in COVID-19 Critically Ill Patients: an Observational Prospective Study
Due to the lack of validated biomarkers to predict disease progression and mortality in COVID-19 ICU-patients, we tested the effectiveness of mid-regional pro-adrenomedullin (MR-proADM) in comparison to C-reactive protein (CRP), procalcitonin (PCT), D-dimer, lactate dehydrogenase (LDH) in predicting outcome.
July 2020
MR-proADM / COVID-19
Adrenomedullin in COVID-19 induced endotheliitis
Despite the exponential growth in research following the rapid spread of SARS-CoV-2 and subsequent COVID-19 pandemic, the underlying pathophysiological mechanisms in COVID-19 patients remain poorly understood. The increased incidence of cardiovascular and thromboembolic complications, immune cell deactivation and sepsis-like multiple organ failure suggests the involvement of multiple pathways.
Adrenomedullin in COVID-19 induced endotheliitis >
July 2020
Financial Reports
Thermo Fisher Scientific Reports Second Quarter 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020....
Thermo Fisher Scientific Reports Second Quarter 2020 Results >
April 2020
MR-proADM / COVID-19
COVID-19 and scarce hospital resources: B·R·A·H·M·S MR-proADM for risk stratification to support decisions on the required level of care
The biomarker mid-regional proadrenomedullin (MR-proADM) allows an easier and more accurate risk assessment in pneumonia patients compared to standard clinical scores (e.g. SOFA), independent of etiology, i.e. viral, bacterial or combined infection. Thus, MR-proADM testing is a useful tool to improve early detection of organ dysfunction and progression to sepsis and septic shock. In conjunction with clinical evaluation and other laboratory findings, MR-proADM can be used as an aid to support decision on patient disposition.
April 2020
Financial Reports
Thermo Fisher Scientific Reports First Quarter 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2020....
Thermo Fisher Scientific Reports First Quarter 2020 Results >
February 2020
Copeptin / Research
Mirjam Christ-Crain Receives 2019 EJE Award for Research Achievements in Copeptin and Vasopressin-Dependent Disorders
Copeptin revealed to be a valuable and reliable diagnostic biomarker in the differential diagnosis of Diabetes insipidus
January 2020
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2019...
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2019 Results >
2019
November 2019
Copeptin / Cardiology
Copeptin now in the new European Society of Cardiology Guidelines for the Diagnosis and Treatment of Pulmonary Embolism 2019
Acute pulmonary embolism is one of the leading causes for cardiovascular death worldwide. Clinicians can now rely on copeptin as a prognostic biomarker for the risk stratification of patients with acute pulmonary embolism, which was recently included in the new guideline from the European Society of Cardiology (ESC) for the diagnosis and treatment of acute pulmonary embolism.
October 2019
Financial Reports
Thermo Fisher Scientific Reports Third Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2019.
Thermo Fisher Scientific Reports Third Quarter 2019 Results >
August 2019
Procalcitonin (PCT)
Success for Brahms as Radiometer’s nullity suit dismissed
Patent holder Brahms has won the next round in the long-standing dispute over procedures for detecting infections. The Federal Patent Court has dismissed a nullity suit from Radiometer
Read the news on JUVE Patent >
July 2019
Copeptin / Cardiology
Multicentre cross-sectional observational registry to monitor the safety of early discharge after rule-out of acute myocardial infarction by copeptin and troponin: the Pro-Core registry
There is sparse information on the safety of early primary discharge from the emergency department (ED) after rule-out of myocardial infarction in suspected acute coronary syndrome (ACS).
Read the article in BMJ Open >
July 2019
Copeptin / Diabetes insipidus
Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study
Differential diagnosis of diabetes insipidus is challenging. The most reliable approach is hypertonic saline-stimulated copeptin measurements.
Read the article in The Lancet >
July 2019
Procalcitonin (PCT)
Validity of B·R·A·H·M·S’ patent confirmed by German Federal Patent Court
Again, B·R·A·H·M·S GmbH (B·R·A·H·M·S) has successfully defended one of its many patents relating to Procalcitonin (PCT) in diagnostics and therapy around sepsis and infectious diseases. In a judgment pronounced on 23 July 2019, the German Federal Patent Court confirmed the validity of the German part of B·R·A·H·M·S’ European patent (EP 2 301 626 B1), and completely rejected a revocation action instigated by Radiometer GmbH and Radiometer Medical ApS.
B·R·A·H·M·S’ patent relates to the use of antibiotics in the treatment of a specific group of patients having defined PCT levels. The broad protection conferred by this patent is justified by the fundamental and innovative nature of the patented invention, which has been recognized and acknowledged by the Federal Patent Court’s in its decision to maintain the patent as granted. Because of this the Court held Radiometer liable to pay all court fees and to reimburse the attorney’s fees incurred by B·R·A·H·M·S for its successful defense.
B·R·A·H·M·S welcomes this decision and continues to vigorously defend and enforce its patent rights relating to PCT in Germany and worldwide.
July 2019
Financial Reports
Thermo Fisher Scientific Reports Second Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2019.
Thermo Fisher Scientific Reports Second Quarter 2019 Results >
May 2019
Procalcitonin / Health Economics
U.S. Health Economic Analysis Demonstrates the Cost Reduction Impact of using B·R·A·H·M·S PCT to Support Antibiotic Stewardship Versus Standard of Care
Outcome shows a reduction in antibiotic days, shorter length of stay, shorter duration of mechanical ventilation, and fewer patients at risk for antibiotic resistance or C.difficile infection lead to incremental reduction of costs of 26 percent in sepsis and 17.7 percent in lower respiratory tract infection
May 2019
Copeptin / Registration
The novel blood biomarker Copeptin is now available for clinical use in early rule-out of acute myocardial infarction and diagnosing water balance disorders
B·R·A·H·M·S Copeptin proAVP KRYPTOR has been registered in Canada allowing for faster, more reliable indirect measurement of vasopressin to improve diagnostic algorithms
May 2019
Copeptin / Research
European Endocrinology Award 2019 for research about Copeptin
Prof. Christ-Crain gave a lecture on “New diagnostic approaches in the diagnosis of Diabetes insipidus” at the opening ceremony of the ECE 2019, because she received the European Endocrinology Award 2019 for her research about Copeptin.
May 2019
Sepsis / Emergency Department (ED)
New Study Results Find That The Blood Biomarker MR-proADM May Prevent Early Hospital Discharge in Patients with Developing Sepsis
Multi-centre analysis shows that incorporation of MR-proADM (mid-regional proadrenomedullin) into an early management of patients with suspected infection protocol may aid rapid clinical decision making in the emergency department
May 2019
Prenatal screening
World Pre-eclampsia Day on May 22nd
May is Pre-eclampsia awareness month and May 22nd is World Pre-eclampsia Day: Thermo Fisher Scientific proudly supports the pre-eclampsia awareness campaign 2019 organized by EFCNI (European Foundation for the Care of Newborn Infants).
Learn more about World Pre-eclampsia Day >
Pre-eclampsia: First trimester screening >
April 2019
Financial Reports
Thermo Fisher Scientific Reports First Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2019.
Thermo Fisher Scientific Reports First Quarter 2019 Results >
March 2019
Copeptin / AdPKD
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
Read the article in Kidney International >
January 2019
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2018.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results >
2018
Thermo Fisher Scientific Declares Quarterly Dividend
November 8, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share...
Thermo Fisher Scientific Declares Quarterly Dividend >
Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018
July 31, 2018
AACC -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest innovations for clinical and translational research during the 2018 American...
Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018 >
Thermo Fisher Scientific Reports Second Quarter 2018 Results
July 25, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 30, 2018. Second Quarter 2018 Highlights Grew...
Thermo Fisher Scientific Reports Second Quarter 2018 Results >
Thermo Fisher Scientific Declares Quarterly Dividend
July 13, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share...
Thermo Fisher Scientific Declares Quarterly Dividend >
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
July 13, 2018
Elecsys® B·R·A·H·M·S PCT™ (procalcitonin) helps clinicians assess presence and severity of certain bacterial infections and patient response to antibiotics
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis >
10th International Workshop on Prenatal Screening
June, 2018
The 10th International Workshop on Prenatal Screening, organized by Thermo Fisher Scientific, took place in Berlin. Almost 170 participants from 28 countries attended the workshop. As already in the previous years the highly scientific program with internationally well recognized speakers makes it a much appreciated event on prenatal screening. For further information about lectures and speakers please get in contact with us.
Contact us >
Read more on prenatal screening >
New Thermo Scientific B·R·A·H·M·S KRYPTOR GOLD Analyzer Instrument Combines Higher Throughput and Maximum Autonomy
June 15, 2018
New KRYPTOR GOLD instrument features the precision and productivity required for clinical specialty diagnostics laboratories and patient diagnosis and prognosis research
Read the News Press Release here >
Find more about B·R·A·H·M·S KRYPTOR GOLD >
Thermo Fisher Scientific supports the European STATIN trial to evaluate pravastatin in the potential prevention of preeclampsia
June 5, 2018
Research results suggest a preventive role of statins in the late-onset form of preeclampsia
Read the News Press Release here >
Thermo Fisher Scientific Supports World Preeclampsia Day on May 22
May, 2018
May 2018 is the pre-eclampsia awareness month with World Preeclampsia Day happening on May 22. Pre-eclampsia is a rare and severe pregnancy complication affecting about 2-8% of pregnancies worldwide. Thermo Fisher Scientific is proud to support this important initiative to create awareness about the symptoms and risks of this disease, but also to inform about the benefits of an early screening test which can be an advise for possible preventive measures and possible prevention in order to improve pregnancy outcome.
EFCNI (European Foundation for the Care of Newborn Infants) >
Thermo Fisher Scientific Reports First Quarter 2018 Results
April 25, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2018.
Thermo Fisher Scientific Reports First Quarter 2018 Results >
New Publication: The use of MR-proADM in assessing disease severity and treatment response in patients with sepsis and septic shock
March 26, 2018
In collaboration with the SepNet Critical Care Trials Group, a new analysis of 1089 patients with sepsis and septic shock across 33 German Intensive Care Units was recently published in Critical Care. MR-proADM could add significant value to identifying patients at risk of further disease progression, the earlier escalation of therapy in patients at risk of treatment failure, and the subsequent de-escalation of treatment and early discharge of low risk patients.
Read the News Press Release here >
Read the full publication here >
Thermo Fisher Scientific Increases Quarterly Dividend
January 31, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.17 per common share, payable on April 16, 2018, to shareholders of record as of March 15, 2018. This reflects a 13% increase over the previous dividend payment of $0.15.
Thermo Fisher Scientific Increases Quarterly Dividend >